Lynch syndrome and polyposis
Thematic group 2
Lynch syndrome and polyposis syndromes are rare inherited conditions where a high lifetime risk to develop gastrointestinal tumours represents the main and dominating feature. The most common of these is bowel cancer (colorectal cancer, CRC). As other hereditary conditions, Lynch and polyposis syndromes follow a certain inheritance pattern and thus are accompanied by an increased recurrence risk in relatives. For most of these syndromes, efficient surveillance programmes are available for patients and healthy mutation carriers to reduce the cancer risk.
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is a group of disorders including Lynch syndrome and familial colorectal cancer type X. Lynch syndrome is one of the most frequent hereditary conditions that increases the risk of developing bowel cancer and a spectrum of other extracolonic tumours, in particular endometrial cancer.
Polyposis syndromes are disorders where multiple polyps are present throughout the gastrointestinal tract, which, if not detected early and removed, might result in colorectal cancer. The occurrence of single colorectal polyps is a common and age-related phenomenon, however, if multiple polyps occur, in particular at young age, a genetic predisposition is likely. Depending on the type of polyps, several polyposis syndromes can be identified, which differ in terms of age at onset, polyp number and distribution, CRC risk and the likelihood to develop tumuors and other symptoms outside the gastrointestinal tract. The most relevant polyposis syndromes can be divided in two main groups:
The thematic leads for Lynch syndrome and polyposis are:
Verena Steinke-Lange, clinical geneticist at the Medical Genetics Center in Munich, Germany | |
Anja Wagner, oncogeneticist at the Erasmus MC in Rotterdam, the Netherlands. | |
|
Nicola Reents, secretary of Familienhilfe Darmkrebs e.V. / Semi-Colon (German patient association for Lynch and Polyposis) | |
Jurgen Seppen, chairman of the Dutch Lynch and Polyposis Foundation. | |
A non-exhaustive list of patient associations for genetic tumour risk syndromes in EU member states can be found here.
Country |
City |
Name of Healthcare Provider |
---|---|---|
Austria |
Innsbruck |
|
Belgium |
Ghent |
|
Leuven |
||
Czech Republic |
Brno |
|
Finland |
Helsinki |
GENTURISFINSN consortium (HUS Helsinki University Hospital and OYS Oulu University Hospital) |
France |
Rouen |
|
Germany |
Bonn |
Center for Hereditary Tumor Syndromes (CHT), University Hospital Bonn |
Dresden |
||
Hamburg |
||
Munich |
||
Hungary |
Pécs |
|
Italy |
Bologna |
|
Milan |
||
Rome |
||
Siena |
||
Lithuania |
Vilnius |
|
Netherlands |
Amsterdam |
|
Groningen |
||
Leiden |
||
Nijmegen |
||
Rotterdam |
||
Norway |
Bergen |
|
Poland |
Szczecin |
Pomeranian Medical University - University Clinical Hospital no 1 |
Portugal |
Lisbon |
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE |
Porto |
||
Spain |
Barcelona |
Hospital Germans Trias I Pujol - lnstitut Catala d'Oncologia |
Sweden |
Stockholm |
*These HCPs are Affiliated Partners of ERN GENTURIS